Research & KnowledgeEvent: September 1, 2026
K36 Therapeutics, Inc. announced the MMSET trial for multiple myeloma patients
Published
Signal category
Research & Knowledge
Quote
“Learn More about our MMSET trial: https://lnkd.in/eaxa59gG”
— K36 Therapeutics, Inc. team
Company
K36 Therapeutics, Inc.
Translating epigenetic modulation of oncogenic pathways NSD2 / MMSET into first-in-class small molecule therapeutics.
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 14 employees
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.
Founded 2021